Live Updates: COVID-19 Cases
  • World 20,837,827
    World
    Confirmed: 20,837,827
    Active: 6,359,116
    Recovered: 13,730,812
    Death: 747,899
  • USA 5,360,488
    USA
    Confirmed: 5,360,488
    Active: 2,378,228
    Recovered: 2,813,125
    Death: 169,135
  • Brazil 3,170,474
    Brazil
    Confirmed: 3,170,474
    Active: 756,734
    Recovered: 2,309,477
    Death: 104,263
  • India 2,399,992
    India
    Confirmed: 2,399,992
    Active: 655,012
    Recovered: 1,697,811
    Death: 47,169
  • Russia 907,758
    Russia
    Confirmed: 907,758
    Active: 175,978
    Recovered: 716,396
    Death: 15,384
  • South Africa 568,919
    South Africa
    Confirmed: 568,919
    Active: 125,880
    Recovered: 432,029
    Death: 11,010
  • Peru 498,555
    Peru
    Confirmed: 498,555
    Active: 134,904
    Recovered: 341,938
    Death: 21,713
  • Mexico 498,380
    Mexico
    Confirmed: 498,380
    Active: 107,079
    Recovered: 336,635
    Death: 54,666
  • Chile 378,168
    Chile
    Confirmed: 378,168
    Active: 16,544
    Recovered: 351,419
    Death: 10,205
  • Spain 376,864
    Spain
    Confirmed: 376,864
    Active: 348,285
    Recovered: ?
    Death: 28,579
  • Iran 336,324
    Iran
    Confirmed: 336,324
    Active: 25,104
    Recovered: 292,058
    Death: 19,162
  • UK 313,798
    UK
    Confirmed: 313,798
    Active: 272,469
    Recovered: ?
    Death: 41,329
  • Saudi Arabia 293,037
    Saudi Arabia
    Confirmed: 293,037
    Active: 32,499
    Recovered: 257,269
    Death: 3,269
  • Pakistan 286,674
    Pakistan
    Confirmed: 286,674
    Active: 16,475
    Recovered: 264,060
    Death: 6,139
  • Bangladesh 269,115
    Bangladesh
    Confirmed: 269,115
    Active: 110,687
    Recovered: 154,871
    Death: 3,557
  • Italy 251,713
    Italy
    Confirmed: 251,713
    Active: 13,791
    Recovered: 202,697
    Death: 35,225
  • Turkey 244,392
    Turkey
    Confirmed: 244,392
    Active: 11,412
    Recovered: 227,089
    Death: 5,891
  • Germany 220,884
    Germany
    Confirmed: 220,884
    Active: 10,808
    Recovered: 200,800
    Death: 9,276
  • France 206,696
    France
    Confirmed: 206,696
    Active: 92,853
    Recovered: 83,472
    Death: 30,371
  • Canada 120,844
    Canada
    Confirmed: 120,844
    Active: 4,690
    Recovered: 107,148
    Death: 9,006
  • China 84,756
    China
    Confirmed: 84,756
    Active: 724
    Recovered: 79,398
    Death: 4,634
  • Netherlands 60,627
    Netherlands
    Confirmed: 60,627
    Active: 54,466
    Recovered: ?
    Death: 6,161
  • Australia 22,358
    Australia
    Confirmed: 22,358
    Active: 8,996
    Recovered: 13,001
    Death: 361
  • S. Korea 14,770
    S. Korea
    Confirmed: 14,770
    Active: 648
    Recovered: 13,817
    Death: 305
  • New Zealand 1,589
    New Zealand
    Confirmed: 1,589
    Active: 36
    Recovered: 1,531
    Death: 22

Whitehead Institute scientists bring new CRISPR tools to strengthen cancer chemotherapy

Author at TechGenyz Science
Cancer Chemotherapy

The gap between cure and cancer is about to get reduced further, as the scientists of Whitehead Institute has deployed the new CRISPR tools for understanding an uncovering new ways to improve the popular Cancer chemotherapy drug named methotrexate.

David Sabatini and his team at Whitehead has pioneered the use of the genome editing system called CRISPR/Cas9. It can analyze large-scale genetic screens of human cells, which further leads to new findings on cellular metabolism for both normal and cancer cells.

Methotrexate is being used for about seven decades now, and if deployed as a multifaceted treatment plan, it can be highly effective. However, it affects not just cancer cells but also damages healthy tissues. This is in the case of treating a form of pediatric leukemia.

Regarding other forms of cancer, the efficacy of the drug is uncertain, and doctors yet do not have ways to comprehend how human bodies respond to the dose. To put it simply, the potential of the drug remains a mystery so far.

This is where CRISPR/Cas9 comes in, providing scientists with a better comprehensive ability to understand the factors involved in methotrexate sensitivity. In a July 11 issue of the journal Nature, the report of the findings states that breaking down the histidine is possible by the drug. Histidine is one of the few amino acids that helps constructs protein, and acts as a critical gatekeeper to the drug, keeping cancer cells from spreading.

The discoveries are to contribute to the understanding of the biology of the Cancer chemotherapy drug, and will as well lead to creating a simple dietary supplement that can expand the therapeutic window and can reduce the toxicity.

Naama Kanarek, a postdoc in the laboratory of Sabatini contemplated on how to apply CRISPR/Cas9 screens with methotrexate. She and her colleagues have now derived an enzyme named FTCD that can contribute to the breakdown of histidine.

There are still challenges ahead and the entire team is working to expand upon the initial discoveries with additional preclinical studies. The aim is to pursue clinical trials for assessing the abilities of histidine in improving methotrexate’s effectiveness in human bodies.

Seems like we humans are finally getting somewhere to discover the cure of cancer. Although the road ahead is still long, the Whitehead discoveries can be dubbed as an ideal kick.

Career

Subscribe